Growth leadership ECI recently appointed a new CEO Brijesh Patel in August 2024 and a Senior Vice President for Strategic Growth & Advisory Khalid Raja in April 2026, signaling an emphasis on strategic expansion, client acquisition, and market diversification which presents upsell and cross-sell opportunities across global life sciences accounts.

Global expansion With headquarters in Marlborough and strategic locations in Costa Rica, Ireland, and India, ECI has a diversified delivery footprint that can support nearshore and offshore engagements, enabling scalable global projects for multinational medical device, pharmaceutical, and biotech clients seeking compliant engineering, validation, and testing services.

Regulatory readiness ECI’s core offering combines quality, regulatory, and compliance with hands-on engineering and testing across development to post-market remediation, aligning closely with market trends toward accelerated product approvals, lifecycle management, and stricter post-market surveillance demands.

Financial strength With estimated revenue in the range of $100M to $250M and a mid-market employment base, ECI sits in a competitive tier where expanding relationships with mid-sized pharma and device firms could yield higher-value services in quality systems, risk management, and compliance automation.

Tech-enabled delivery ECI employs a tech stack including cloud, analytics, and APIs (AWS, Google Analytics, Bing Ads, ISO frameworks) which can be leveraged to offer data-driven quality improvements, digital transformation, and scalable compliance programs to clients seeking modern, auditable solutions.